drugset / Trial / NCT02799485
sEphB4-HSA in Treating Patients With Kaposi Sarcoma
Phase 2
Completed
23 enrolled
AIDS Malignancy Consortium
National Cancer Institute (NCI) · collabThe Emmes Company, LLC · collabUniversity of Arkansas · collabVasgene Therapeutics, Inc · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies recombinant EphB4-HSA fusion protein (EphB4-HSA) in treating patients with Kaposi sarcoma. Recombinant EphB4-HSA fusion protein may block the growth of blood vessels that provide blood to the cancer, and may also prevent cancer cells from growing.
Timeline
- Start
- 2018-02-13
- Primary completion
- 2025-02-19
- Completion
- 2025-02-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EphB4-HSA | Protein / enzyme biologic | 10 mg/kg | Intravenous |
| Subject | EphB4-HSA | Protein / enzyme biologic | 15 mg/kg | Intravenous |